Agonist and antagonist-dependent internalization of the human vasopressin V2 receptor

被引:35
|
作者
Pfeiffer, R
Kirsch, J
Fahrenholz, F
机构
[1] Univ Mainz, Inst Biochem, D-55099 Mainz, Germany
[2] Max Planck Inst Hirnforsch, D-60528 Frankfurt, Germany
关键词
vasopressin; human V-2 receptor; receptor internalization; desensitization; antagonists;
D O I
10.1006/excr.1998.4159
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this report we demonstrate that in HEK293 cells stably expressing the human V-2 vasopressin receptor, ligand-induced internalization of the hormone receptor occurs via the clathrin-dependent pathway. Studies of receptor trafficking either by direct visualization of the V-2 receptor by confocal microscopy or binding experiments show a rapid internalization (half-time 6-7 min), Blocking of the clathrin-dependent pathway by hypertonic sucrose increased vasopressin-induced cellular cAMP production and decreased the desensitization of the V-2 receptor-adenylyl cyclase system. Thus, internalization appears to be a major regulatory mechanism terminating vasopressin action in HEK293 cells. Two antagonists of the vasopressin V-2 receptor exerted different effects on receptor internalization, as determined by confocal fluorescence microscopy, The nonpeptidic antagonist OPC31260 did not induce any visible receptor internalization, whereas the peptidic antagonist d(CH2)(5)[D-Tyr(Et)(2),Val(4),Lys(8), Tyr-NH29]VP induced a slow but substantial receptor internalization. These results suggest that long-term treatment with peptidic V-2 receptor antagonists might lead to desensitization. (C) 1998 Academic Press.
引用
收藏
页码:327 / 339
页数:13
相关论文
共 50 条
  • [31] Vasopressin V2 receptor/bioligand interactions
    Czaplewski, C
    Kazmierkiewicz, R
    Ciarkowski, J
    LETTERS IN PEPTIDE SCIENCE, 1998, 5 (5-6): : 333 - 335
  • [32] Vasopressin V2 receptor/bioligand interactions
    Cezary Czaplewski
    Rajmund Kaźmierkiewicz
    Jerzy Ciarkowski
    Letters in Peptide Science, 1998, 5 : 333 - 335
  • [33] Vasopressin V2 Receptor Antagonist Inhibits Cardiac Remodeling with Old Myocardial Infarction in Rats
    Yamazaki, Takanori
    Nakamura, Yasuhiro
    Izumi, Yasukatsu
    Hanatani, Akihisa
    Muro, Takashi
    Yoshiyama, Minoru
    JOURNAL OF CARDIAC FAILURE, 2011, 17 (09) : S149 - S150
  • [34] Synthesis of a 2-pyrrolidinol metabolite of OPC-51803, a vasopressin V2 receptor agonist
    Kawano, Y
    Matsubara, J
    Kitano, K
    Ohtani, T
    Otsubo, K
    Komatsu, M
    Uchida, M
    Tabusa, F
    HETEROCYCLES, 2003, 61 : 551 - +
  • [35] Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan
    Kramers, Bart J.
    van Gastel, Maatje D. A.
    Boertien, Wendy E.
    Meijer, Esther
    Gansevoort, Ron T.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 73 (03) : 354 - 362
  • [36] Mapping peptide antagonist binding sites of the human V1a and V2 vasopressin receptors
    Mouillac, B
    Phalipou, S
    Cotte, N
    Balestre, MN
    Hibert, M
    Manning, M
    Barberis, C
    VASOPRESSIN AND OXYTOCIN: MOLECULAR, CELLULAR, AND CLINICAL ADVANCES, 1998, 449 : 359 - 361
  • [37] Lithium effectively complements vasopressin V2 receptor antagonist in the treatment of hyponatraemia of SIADH rats
    Kazama, Itsuro
    Arata, Tomohiro
    Michimata, Mari
    Hatano, Ryo
    Suzuki, Michiko
    Miyama, Noriyuki
    Sanada, Satoru
    Sato, Akira
    Satomi, Susumu
    Ejima, Yutaka
    Sasaki, Sei
    Matsubara, Mitsunobu
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (01) : 68 - 76
  • [38] Total synthesis of SR 121463 A, a highly potent and selective vasopressin V2:: Receptor antagonist
    Venkatesan, H
    Davis, MC
    Altas, Y
    Snyder, JP
    Liotta, DC
    JOURNAL OF ORGANIC CHEMISTRY, 2001, 66 (11): : 3653 - 3661
  • [39] VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist
    Chan, PS
    Coupet, J
    Park, HC
    Lai, F
    Hartupee, D
    Cervoni, P
    Dusza, JP
    Albright, JD
    Ru, X
    Mazandarani, H
    Tanikella, T
    Shepherd, C
    Ochalski, L
    Bailey, T
    Lock, TYW
    Ning, XP
    Taylor, JR
    Spinelli, W
    VASOPRESSIN AND OXYTOCIN: MOLECULAR, CELLULAR, AND CLINICAL ADVANCES, 1998, 449 : 439 - 443
  • [40] Synthesis and characterization of orally active nonpeptide arginine vasopressin V2 receptor antagonist.
    Ohkawa, T
    Setoi, H
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 104 - MEDI